There was a clear differential protein enrichment between EV and SP fractions, of which gene set enrichment analysis showed differential biological functions and cellular origin. Moreover, urine samples before and after local prostate cancer treatment were enriched in different proteins. This applied to both the EV and SP fractions. A significant over-representation of proteins involved in RNA and protein metabolism was found in uEV prior to therapy, while proteins enriched in SP fractions were related to energy metabolism and cytoskeleton dynamics. Proteins enriched in uEV after local prostate cancer treatment were mainly responsible for the classic transport function of EV.
INTRODUCTION AND OBJECTIVES: Hyperspectral imaging (HSI)
is an emerging modality used to obtain spatially resolved spectral images that provides diagnostic information on tissue physiology and morphology. The hyperspectral image data of prostate cancer tissues from prostatectomy specimen were analyzed to determine its clinical utility.
METHODS: After obtaining the institutional review board 0 s approval, 22 prostate cancer specimens obtained from radical prostatectomy were evaluated. A randomly selected square of 5Â5 mm pixel was identified on each specimen slices. We evaluated 209 pixels from 132 cancer and 77 normal areas. The prostatic glands were sliced at 4mm intervals perpendicular to the urethra. The HSI system was used to obtain hyperspectral images of the specimens. This system is capable of obtaining reflectance images with a size of 1920Â1440 over 400 to 700nm (Dl[15 nm) . CIELAB values represents colors using the coordinates in a uniform color space consisting of lightness variable L* and chromaticity indices a* and b*. CIELAB values are calculated as ([L*]2þ[a*]2þ[b*]2)1/2. The CIELAB of malignant and normal areas were calculated, respectively, and plotted in the color space. The association between CIELAB and tumor characters such as Gleason score (GS) classification was determined.
RESULTS: Higher GS of the cancer tissue was associated with a relatively high-intensity wavelength range. The mean CIELAB data were not significantly different between the normal areas and GS 3þ3 tumors (p[0.41). However, the mean CIELAB data of GS 3þ4!tumors were significantly higher than those of GS 3þ3 tumors (meanAESD, 67.5AE1. METHODS: We profiled the transcriptomic and copy number profile of 40 Gleason Grade Group 2 tumors treated by prostatectomy. Twenty tumors were mpMRI invisible (PI-RADSv2: 1-2), while 20 tumors were visible (PI-RADsv2: 5).
RESULTS: Copy number aberrations (CNAs) and mRNA abundance were analyzed. Univariate analysis identified 102 transcripts differentially abundant between visible vs invisible tumors. Unexpectedly, non-coding transcripts comprised the majority of differentially abundant RNAs (57/102 transcripts). In particular, snoRNAs were significantly more likely to have elevated abundance in visible tumors (OR[4.4; . Perhaps most provocatively, SCHLAP1, a lncRNA linked to PCa progression, was more abundant in visible tumors (log2FC[3.2, FDR[0.028; Figure 1A ). Additionally, visible tumors harbored significantly more unstable genomes, quantified as the percentage of the genome altered via CNAs (PGA; P[0.036; log2FC[2.3; Figure 1B ). Concordantly, intraductal carcinoma (IDC) and cribriform architecture (CA) were enriched in PI-RADSv2 5 tumors (OR [ 7.0; P[0.031; Figure 1C ). Finally, we quantified a synergy between hallmarks and found the odds of visibility to be 10-fold higher with co-occurrence of !2 hallmarks (OR[10; P[5.7x10-3; Figure 1D ). Nimbosus hallmarks synergized with snoRNA levels to predict visibility with 87% accuracy, superior to the 60% accuracy of the clinical signature, suggesting elevated snoRNA abundance may be a novel hallmark of nimbotic tumors (AUC[0.87, 95% CI: 0.75-0.99; Figure 1E ).
CONCLUSIONS: This work points to a novel model for the origin of mpMRI visibility involving the co-occurrence of multiple aggressive hallmarks, reminiscent of nimbosus. These hallmarks include IDC/CA pathology, increased PGA and overexpression of key non-coding transcripts, such as SCHLAP1 and snoRNAs. This cooccurrence results in an aggressive tumor phenotype, with poor patient outcome.
INTRODUCTION AND OBJECTIVES:
The need to differentiate patients at risk for developing aggressive prostate cancer (CaP) from those at risk for less aggressive disease has led to efforts to identify genetic markers to predict disease course and personalize treatment. Prior work from our group identified 13 single nucleotide polymorphisms (SNPs) in 12 cell cycle genes that were associated with risk of aggressive CaP. We sought to replicate those results in the EuropeanAmerican population of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
METHODS: We focused on variants associated with aggressive CaP in the prior cohort, which included 13 SNPs in 12 genes (CCNC, CCND3, CCNG1, CCNT2, CDK2, CDK6, MDM2, SKP2, TERF2, WEE1, YWHAB, YWHAH). Variants were genotyped using Pyrosequencing assay. Patients were classified into high risk (Gleason!8, pT3b, Nþ, Mþ), low risk (Gleason 7, pT3a, N0, M0) or non-cancer control groups based on clinicopathologic characteristics. Logistic regression analysis was used to compare genotype frequencies of each variant between groups using the dominant model. RESULTS: There were 108 aggressive and 1080 nonaggressive CaP patients, and 1155 controls. CDK6 (rs8) was associated with increased risk of any CaP (OR 1.2, 95% CI 1.02-1.42; p[0.032) and high risk disease (OR 1.63, 95% CI 1.09-2.42; p[0.017) vs. controls. This was in contrast to the prior study where the CDK6 variants were protective against aggressive CaP . CCNG1 (rs11541970) approached significance (OR 1.86, p[0.052) between high risk and control groups, but its effect was also opposite in direction compared to the previous study. CCNC (rs330812) conferred a protective effect consistent with the prior study, but did not reach statistical significance (OR 0.69, p[0.101) . No associations with any cell cycle gene variants were detected when comparing high and low risk patients. CONCLUSIONS: Our study did not replicate our prior results. CDK6 predicted increased risk of developing any CaP and high risk CaP. However, directionality was opposite to the prior study, indicating that this variant is unlikely to be a true predictor of increased risk of or protection from aggressive CaP. CCNC demonstrated a protective effect in both studies, but did not reach statistical significance in our analysis. Nonetheless, further work to explore its role in predicting risk of aggressive disease is warranted given the absence of validated SNPs in the identification of aggressive CaP.
( 
The presence of tertiary pattern 5 (TP5) on radical prostatectomy specimens has been associated with worse long-term outcomes. However, the molecular underpinnings of TP5 is poorly understood. We hypothesized that a comparative analysis of transcript profiles between Gleason matched tumors with and without TP5 would provide us a unique opportunity to identify genes that contribute to TP5 and investigated if genomic features of TP5 could explain the poor clinical outcomes associated with this disease subtype.
METHODS: Data from 159 men who underwent radical prostatectomy and had Gleason Grade Group (GGG) 3 or 4 without primary or secondary pattern 5 on final pathology were considered. All patients had Decipher diagnostic test (assesses 5-year risk of metastasis post-RP). Additionally, transcript profiles and SCAN-normalized expression of coding genes were available for all 159 patients.
The relationship between Decipher score and the presence of TP5 was investigated by means of linear and binary logistic regression. A differential transcriptomic analysis between patients with and without TP5 was performed in order to identify the genes associated with TP5 as a proxy of early dedifferentiation. The prognostic role of these genes in identifying patients with worse progression-free survival (PFS) and overall survival (OS) was then evaluated by utilizing The Cancer Genome Atlas provisional (TCGAp) accessed through the cBioPortal for Cancer Genomics.
RESULTS: Overall, 52/159 (33%) patients had GGG 3-4 disease with TP5 while 107/159 (67%) harbored GGG 3-4 disease alone. The presence of TP5 was associated with a higher Decipher score (B: 0.07, 95% CI: 0.02, 0.13, p[0.04) and a higher likelihood of falling within the intermediate-or high-risk categories (OR: 3.34, 95% CI: 1.34, 8.35, p[0.01) rather than the low-risk category. Analysis of microarray data revealed an 18 gene signature that was differentially expressed in patients with TP5. Genes CDKN2B, CHIT1, PDSS1, CDK4, SRD5A1, CXCR6, DCK, PLK1, CDC20, FGF14, FLRT2, RARA, and CXXC5 were over-expressed in the TP5 cohort.A systematic analysis of genes in the TCGAp revealed that overexpression of CDKN2B, PLK1, and CDC20 was associated with worse PFS. When combined, the group harboring overexpression of at least one of these genes had a 5-year PFS rate of 50% versus 74% in the group without overexpression, p<0.001. CONCLUSIONS: Our study has elucidated unique genomic features of TP5 while confirming previous findings that patients harboring TP5 tend to have worse prognosis. Analysis of transcript profiles revealed that the expression levels of 18 genes were significantly altered in TP5 positive versus negative specimens. Furthermore, there is evidence that alterations in the expression levels of cell cycle genes CDKN2B, PLK1, and CDC20 are critical drivers of TP5. Analysis of independent prostate cancer datasets demonstrated that the overexpression of all three genes was associated with worse PFS. To the
